Doug Ingram

Pharma

Sarepta sees delays in treatment after Elevidys death report

Some families have delayed treatment with the DMD gene therapy following the report of a patient’s death but Sarepta believes the impact is temporary.

Angus Liu May 7, 2025 8:03am

Sarepta's Elevidys blows sales expectations out of the water

Nov 7, 2024 3:43pm

Sarepta CEO Ingram nabs $57M in 2017 pay

May 7, 2018 12:36pm

The companys newest additions include a global director of revenue management global director of sales and a food beverag

Sarepta’s CEO pick draws praise, takeover talk from analysts

Jun 29, 2017 5:58am